门急诊破伤风抗毒素合理用药分析Analysis of Rational Drug Use of Tetanus Antitoxin at Outpatient and Emergency Departments
蔡云峰,何秀屏
CAI Yunfeng,HE Xiuping
摘要(Abstract)：
目的探讨门诊、急诊处方使用破伤风抗毒素(Tetanus antitoxin,TAT)的合理性。方法抽取某院1 500例应用TAT的门急诊处方,参照国内外的外伤处理指南,并结合患者免疫接种史对伤口破伤风风险进行分类,对TAT应用的合理性进行分析。结果根据统计分析结果,51.68%的门急诊外伤患者没有破伤风风险,不需要注射TAT。结论 TAT存在大量的不合理应用,皮肤过敏试验及注射增加了工作量,脱敏注射增加了医疗风险,需要进行规范。
OBJECTIVE To explore the rationality of drug use of tetanus antitoxin( TAT) in the outpatient and emergency departments. METHODS 1 500 prescriptions of outpatient and emergency departments of a hospital were drawed and the rationality of drug use of TAT was analyzed by referring to the domestic and overseas guidelines for the treatment of trauma and classifying the tetanus risks of trauma combining with patient's history of immunization. RESULTS According to the statistical analysis results,51.68%patients with trauma history had not tetanus risk,thus it's unnecessary to inject TAT. CONCLUSION There are many cases with irrational drug use of TAT; skin allergy test and injection also increased the workload,and desensitization injection may increase medical risk,which needs standardization.
关键词(KeyWords)：
破伤风;破伤风抗毒素;合理用药
tetanus;tetanus antitoxin(TAT);rational drug use
基金项目(Foundation):
作者(Author):
蔡云峰,何秀屏
CAI Yunfeng,HE Xiuping
参考文献(References)：
- [1]贾文祥.医学微生物学[M].2版.北京:人民卫生出版社,2010:165-167.
- [2]陈孝平.外科学[M].2版.北京:人民卫生出版社,2010:1701-1712.
- [3]桑福德,范洪伟.热病-桑福德抗微生物治疗指南[M].44版.北京:中国协和医科大科出版社,2014:221.
- [4]唐路平,张茂.美国野外医学会关于恶劣环境下伤口初步处理指南[J].中华急诊医学杂志,2014,23(12):1307-1308.
- [5]WHO.Prevention and management of wound infection[EB/OL].http://www.who.int/hac/techguidance/tools/guidelines_prevention_and_management_wound_infection.pdf,2016.6.
- [6]中华医学会创伤学分会创伤感染学组,中华医学会急诊医学分会创伤学组.创伤后抗菌药物预防性应用专家共识[J].中华急诊医学杂志,2016,25(10):1224-1308.
- [7]CDC.Diphtheria,Tetanus,and Pertussis:Recommendations for Vaccine Use and Other Preventive Measures Recommendations of the Immunization Practices Advisory Committee[J].MMWR,1991,40(10);1-28.
- [8]邵晓萍,罗耀星,雷仁宇,等.广东省2003年儿童计划免疫接种率调查[J].华南预防医学,2005,31(1):32-34.
- [9]谢莘,罗耀星,雷仁宇,等.广东省珠江三角洲地区儿童计划免疫接种率调查[J].华南预防医学,2005,31(6):31-32.
- [10]曹雷,王华庆,郑景山,等.中国扩大国家免疫规划疫苗接种率调查分析[J].中国疫苗和免疫,2012,18(5):419-424.
- [11]吴伟文,黄凯文,梁锦诗,等.门诊破伤风抗毒素合理用药分析[J].现代医药卫生,2012,28(12):1774-1775.
- [12]张晓庆,刘生友.破伤风抗毒素致过敏性休克82例文献分析[J].药物流行病学杂志,2013,22(5):274-275.
- [13]徐英元,李玉平,付式海,等.TAT预防破伤风作用探讨[J].中国药业,1998,9(4)∶38-39.
- [14]吴阶平,裘法祖.黄家驷外科学[M].6版(上册).北京:人民卫生出版社,2007:91-92.
- [15]余超,徐玉茗,徐瑾,等.破伤风抗毒素临床应用及安全性研究进展[J].中国药物警戒,2016,13(1):36-41.
- [16]吴瑞萍,胡亚美,江载芳,等.诸福棠实用儿科学[M].6版.北京:人民卫生出版社,1998:873-873.
- [17]杨贵博,王传林.破伤风预防现状及常见误区[J].创伤外科杂志,2014,16(1):94-96.
- [18]王淑梅,蔡银炜.浅谈破伤风抗毒素在临床的合理使用[J].青岛医药卫生,2013,45(3):205-206.
- [19]杨苏文,王红,何文秀.破伤风药物临床使用规范浅谈[J].西南国防医药,2008,18(1):69-70.
- [20]WHO.Current recommendations for treatment of tetanus during humanitarian emergencies[EB/OL].http://www.who.int/diseasecontrol_emergencies/who_hse_gar_dce_2010_en.pdf,WHO technical note 2010.2.
- [21]周海云,江丽君.人破伤风免疫球蛋白及其应用[J].微生物学免疫学进展,2006,34(2):84-86.
- [22]何庆,丛鲁红.破伤风免疫球蛋白在破伤风治疗中的应用[J].中国生物制品学杂志,2007,20(5):391-392.
- [23]杨胜军,刘军生,高祥云,等.人破伤风免疫球蛋白与马血清破伤风抗毒素临床应用[J].中国急诊医学杂志,2004,13(5)∶350-351.
- [24]破伤风人免疫球蛋白Human Tetanus Immunoglobulin说明书[Z].华兰生物工程股份有限公司.